Imaging of metastatic medullary carcinoma of the thyroid with 131I-meta-iodobenzyl guanidine

Poston, Graeme J.; Thomas, Asha; MacDonald, D; D, Karvounaris; Henderson, B. L.; George, Penny; Lynn, John A.; Lavender, J. P.

doi:10.1097/00006231-198604000-00003

Cited by 10 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding strongly suggests to systematically immunostain Ki-67 in MTC samples in order to select patients who are expected to be positive at the FDG-PET. As far as MIBG is concerned, its uptake was found to be unrelated to tumor mass and calcitonin secreting activity as well as it was independent by tumor proliferation activity as expressed by Ki-67 score, confirming that MIBG uptake in MTC is unreliable and unpredictable (Poston et al 1986). The degree of incorporation of amine precursors seems to be the only mechanism explaining the positive MIBG uptake in a subgroup of MTC (Oishi et al 1986).…”

Section: Discussionmentioning

confidence: 85%

Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer

Faggiano¹,

Grimaldi²,

Pezzullo³

et al. 2009

Endocrine-Related Cancer

View full text Add to dashboard Cite

In patients with postoperative persistent medullary thyroid cancer (MTC), the tumor detection rate is generally low for most of the imaging techniques now available. The aim of this study was to investigate if the clinico-biological profile of the tumor may indicate which imaging technique to perform in order to identify postoperative persistent or relapsing MTC foci. Thirty-five consecutive MTC patients with detectable and progressively increasing postoperative serum concentrations of calcitonin were enrolled in the study. The detection rates of 18F-deoxy-D-glucose (FDG)-positron emission tomography (PET), somatostatin receptor scintigraphy (SRS), and 131I-metaiodobenzylguanidine scintigraphy (MIBG) were compared in relation with calcitonin and carcinoembryonic antigen serum concentrations, Ki-67 score and results of conventional imaging techniques (CIT). FDG-PET positivity was significantly associated with calcitonin serum concentrations O400 pg/ml and Ki-67 score O2.0% (P!0.05), while SRS positivity was associated with calcitonin serum concentrations O800 pg/ml (P!0.05). SRS positivity significantly correlated with tumor appearance at CIT (P!0.01), while FDG-PET was positive in nine CIT-negative patients. The secretive and proliferative tumor profile may guide the choice of the imaging technique to use in the follow-up of patients with MTC. A Ki-67 score O2.0% suggests to perform a FDG-PET in addition to conventional imaging. Calcitonin secretion predicts both FDG-PET and SRS uptake but SRS positivity is generally found only in patients with well defined MTC lesions that are also detectable at the conventional imaging examination. MIBG outcome is not predicted by any clinico-biological factors here investigated.

show abstract

Section: Discussionmentioning

confidence: 85%

Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer

Faggiano¹,

Grimaldi²,

Pezzullo³

et al. 2009

Endocrine-Related Cancer

View full text Add to dashboard Cite

show abstract

“…In addition to conventional morphological imaging, various nuclear medicine investigations have been performed for the detection by scintigraphy of MTC recurrences: these in-elude the use of agents such as iodine-labelled meta-iodobenzyl guanidine [6], pentavalent 99mTc-dirnercaptosuccinic acid [7], labelled somatostatin analogues [8,9] and radiolabelled monoclonal antibodies against carcinoembryonic antigen (CEA) [10][11][12][13]. All these modalities have proven capable of detecting small recurrences of MTC, but their sensitivity is generally limited by high back ground or low tumour uptake.…”

Section: Introductionmentioning

confidence: 99%

Targeting Medullary Thyroid Carcinomas with Bispecific Antibodies and Bivalent Haptens

Rouvier¹,

Gautherot²,

Meyer³

et al. 1997

Horm Res

View full text Add to dashboard Cite

The present article reviews the clinical trials that have been performed in recurrent medullary thyroid carcinoma patients with the Affinity Enhancement System. This technique uses bispecific antibodies to target radiolabelled bivalent haptens to tumour cells. Its sensitivity in the detection of known tumour sites is high (90%) and this technique also achieves good sensitivity (61 %) in the detection of occult disease as revealed by abnormal thyrocalciton in blood levels. Due to its high targeting capacity, this technique is now considered for use as a therapeutic agent in medullary thyroid carcinoma patients.

show abstract

Diagnostic Nuclear Medicine Investigations in the Management of Thyroid Cancer

Clarke

2006

Practical Management of Thyroid Cancer

View full text Add to dashboard Cite

Imaging of metastatic medullary carcinoma of the thyroid with 131I-meta-iodobenzyl guanidine

Cited by 10 publications

References 0 publications

Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer

Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer

Targeting Medullary Thyroid Carcinomas with Bispecific Antibodies and Bivalent Haptens

Diagnostic Nuclear Medicine Investigations in the Management of Thyroid Cancer

Contact Info

Product

Resources

About